Publications Placebo Response and Remission Rates in Randomised Trials of Induction and Maintenance Therapy for Ulcerative Colitis Citation Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 Sep 8;9(9):CD011572. doi: 10.1002/14651858.CD011572.pub2. PMID: 28886205; PMCID: PMC6483671. Abstract Background: It is important to minimize placebo rates in randomised controlled trials (RCTs) to efficiently detect treatment differences between interventions. Historically, high placebo rates have been observed in clinical trials of ulcerative colitis (UC). A better understanding of factors influencing placebo rates may lead to more informed clinical trial design. Tags Aminosalicylic Acids, Anti-Inflammatory Agents, Anti-Inflammatory Agents Non-Steroidal, Biological Products, Complications, Diagnosis, Drug Therapy, Gastrointestinal Hemorrhage, Induction Chemotherapy, Maintenance Chemotherapy, Placebo Effect, therapeutic use, Ulcerative Colitis Read More
